Key result
Thrombophilia testing in VTE is linked to ~62% higher recurrent VTE and increased anticoagulant use.
Why the study?
The value of thrombophilia test acquisition in improving risk prediction beyond clinical presentation remains unknown.
Does thrombophilia testing improve outcomes or risk prediction in adult patients with a first diagnosis of VTE?
Population
747 propensity-matched pairs of adult patients with first diagnosis of VTE
Comparison
Thrombophilia testing vs no thrombophilia testing
Design
Single-center retrospective propensity-matched cohort study
Authors
Loading...
Thrombophilia testing acquisition was associated with higher recurrent VTE; leaves open its added value for risk prediction beyond clinical factors.
Cohort (n=1,494)
No
Does thrombophilia testing improve outcomes or risk prediction in adult patients with a first diagnosis of VTE?
Absolute Event Rate: 46.1% vs 28.5%
p-value: p=<0.001
The decision to perform thrombophilia testing is associated with a higher risk of recurrent VTE and longer anticoagulation use, but the test result itself does not predict these outcomes, suggesting testing acts as a marker of perceived clinical risk rather than a useful prognostic tool.
Kozák et al. (2019) conducted a cohort in Venous thromboembolism (VTE) (n=1,494). Thrombophilia testing vs. No thrombophilia testing was evaluated on Recurrent VTE (p=<0.001). Thrombophilia testing in patients with VTE was associated with higher rates of recurrent VTE (46.1% vs 28.5%; P<0.001) and 12-month anticoagulant use (53.9% vs 37.1%; P<0.001) compared to no testing.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: